

## **Intracranial Germinoma Treatment according Brazilian Consortium Protocol**




Natalia Dassi<sup>1</sup>, Nasjla Saba Silva<sup>1</sup>, Bruna Mançano<sup>2</sup>, Daniela Barbosa Almeida<sup>1</sup>, Sergio Cavalheiro<sup>1</sup>, Patricia A Dastoli<sup>1</sup>, Maria Teresa S Alves<sup>1</sup>, Frederico A Silva<sup>1</sup>, Sidnei Epelman<sup>3</sup>, Simone Aguiar<sup>4</sup>, Jonathan L Finlay<sup>5</sup>, Andrea Maria Cappellano<sup>1</sup>


1. IOP-GRAACC-UNIFESP, SP; 2. Hospital Amor Barretos, SP; 3. Hospital Santa Marcelina/TUCCA, SP; 4. CIPED/UNICAMP, SP; 5. Nationwide Children's Hospital, Ohio, EUA

Introduction: Primary central nervous system (CNS) germ cell tumors (GCT) account for 2-3% of brain tumors in children/adolescents in Western hemisphere and are classified according to histological components as germinomas and non-germinomatous germ cell tumors (NGGCT). Methods: Since 2013, 58 patients with histologic and/or tumor marker (TM) of CNSGCT were diagnosis, 43 of them were germinoma with/without HCGβ levels≤200mIU/ml, five of them between 100-200mIU/ml.





Results: Mean age 13,2 years, 29 males.







## **Chemotherapy Response and Toxicity:**












After 2 cycles- PR CSF HCGβ- 5 mIU/ml Serum HCGβ (-)



After s 4 cycles- CR -> RT CSF/ erum HCGβ (-) 6 years out of treatment.

## EF and OS 40m follow-up- 100%

<u>Conclusion</u>: The treatment is tolerable and VFI dose reduction to 18Gy seems to preserve efficacy even in the cases of HCG levels between 100-200mlU/ml.